GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

A new survey released by IBM and Silico Research reveals that if life science companies fail to collaborate, they risk costly delays in the production of new medicines, medical devices, diagnostics, and support services. The survey also spotlights a paradox regarding alliances between larger and smaller life science firms.


During this week's GEN podcast, IBM's Salima Lin defines the paradox and offers suggestions on how biotech and pharmaceutical companies can work together more effectively. She also lists the key factors that drive companies to collaborate with one another and discusses what small companies look for in collaborations with larger firms and vice versa.


Lin talks about survey results indicating which large life science firms are considered good partners and why. She also takes a close look at those big pharma companies found to be lacking in the qualities that make for a promising partner.


Lin explores those aspects of a life science alliance that need to be measured to assess its productivity and describes four steps companies should follow to become more sought-after partners.
Salima Lin is Global Strategy and Market Development Leader for, IBM's Life Sciences Industry. In this capacity, she helps with developing IBM's global Life Sciences strategies and its portfolio of client solutions and investments. She has over 15 years’ experience in the pharmaceutical and life sciences industry, with particular expertise in the intersection of science, business and technology. These include business model growth strategies, R&D growth strategies, genomics/proteomics strategies, modeling and simulation strategies, development of collaboration/partnership R&D models, Managed Markets strategies, and disease management. strategies. Salima has a Master’s degree in health management and business strategy from Harvard University. She has also written and contributed to numerous publications over the last few years, including: "Imperfect Harmony: Alliances within the life sciences industry", "Cultivating Innovation beyond Corporate Walls: Alliances between the life sciences industry and academia", "The Enterprise of the Future: 2008 Global CEO Study – Life Sciences Edition," "A marriage of minds: Making biopharmaceutical collaborations work" and "The power of many: ABCs of collaborative innovation throughout the extended enterprise.”" She can be reached at salima.lin@us.ibm.com.

Add a comment

  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?